Abstract:Background: Identifying microbial targets in irritable bowel syndrome (IBS) and other disorders of gut-brain interaction (DGBI) is challenging due to the dynamic nature of microbiota-metabolite-host interactions. SCFA are key microbial metabolites that modulate intestinal homeostasis and may influence IBS pathophysiology. We aimed to assess microbial features associated with short chain fatty acids (SCFA) and determine if features varied across IBS subtypes and endophenotypes. Among 96 participants who were screened, 71 completed the study. We conducted in-depth investigations of stool microbial metagenomes, stool SCFA, and measurable IBS traits (stool bile acids, colonic transit, stool form) in 41 patients with IBS (IBS with constipation [IBS-C] IBS with diarrhea [IBS-D]) and 17 healthy controls. We used partial canonical correspondence analyses (pCCA), conditioned on transit, to quantify microbe-SCFA associations across clinical groups. To explore relationships between microbially-derived SCFA and IBS traits, we compared gut microbiome-encoded potential for substrate utilization across groups and within a subset of participants selected by their stool characteristics as well as stool microbiomes of patients with and without clinical bile acid malabsorption. Results: Overall stool microbiome composition and individual taxa abundances differed between clinical groups. Microbes-SCFA associations differed across groups and revealed key taxa including Dorea sp. CAG:317 and Bifidobacterium pseudocatenulatum in IBS-D and Akkermansia muciniphila and Prevotella copri in IBS-C that that may drive subtype-specific microbially-mediated mechanisms. Strongest microbe-SCFA associations were observed in IBS-D and several SCFA-producing species surprisingly demonstrated inverse correlations with SCFA. Fewer bacterial taxa were associated with acetate to butyrate ratios in IBS compared to health. In participants selected by stool form, we demonstrated differential abundances of microbial genes/pathways for SCFA metabolism and degradation of carbohydrates and mucin across groups. SCFA-producing taxa were reduced in IBS-D patients with BAM. Conclusion Keystone taxa responsible for SCFA production differ according to IBS subtype and traits and the IBS microbiome is characterized by reduced functional redundancy. Differences in microbial substrate preferences are also linked to bowel functions. Focusing on taxa that drive SCFA profiles and stool form may be a rational strategy for identifying relevant microbial targets in IBS and other DGBI.

Gut Microbiota-Derived Metabolites in Irritable Bowel Syndrome

Intestinal Crosstalk between Bile Acids and Microbiota in irritable bowel syndrome

Integrated Multi-Omics Data Analysis Reveals Altered Metabolome Activity and Microbiome Composition in Irritable Bowel Syndrome

Gut Microbiota and Irritable Bowel Syndrome: Status and Prospect

Microbiome and Its Role in Irritable Bowel Syndrome

Gut Non-Bacterial Microbiota: Emerging Link to Irritable Bowel Syndrome

Microbiota-Short Chain Fatty Acid Relationships Underlie Clinical Heterogeneity and Identify Key Microbial Targets in Irritable Bowel Syndrome (IBS)

IDENTIFICATION OF GUT MICROBIOTA AND METABOLITES SIGNATURE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME

The function of the gut microbiota–bile acid–TGR5 axis in diarrhea-predominant irritable bowel syndrome

The Role of Short Chain Fatty Acids in Irritable Bowel Syndrome

Altered metabolome and microbiome features provide clues in understanding irritable bowel syndrome and depression comorbidity

Interplay between gut microbiota and bile acids in diarrhoea-predominant irritable bowel syndrome: a review

Cross-Cohort Gut Microbiome Signatures of Irritable Bowel Syndrome Presentation and Treatment

Aggregation and Self-Assembly of Hydrophobins from Trichoderma Reesei: Low-Resolution Structural Models

Neurotransmitter and Intestinal Interactions: Focus on the Microbiota-Gut-Brain Axis in Irritable Bowel Syndrome

Alterations in Gut Microbiome Composition and Function in Irritable Bowel Syndrome and Increased Probiotic Abundance with Daily Supplementation

Aberrant Gut-To-Brain Signaling in Irritable Bowel Syndrome - The Role of Bile Acids

Gut microbiota and intestinal immunity—A crosstalk in irritable bowel syndrome

Altered Molecular Signature of Intestinal Microbiota in Irritable Bowel Syndrome Patients Compared with Healthy Controls: A Systematic Review and Meta-Analysis

The Relationship Between Gut Microbiota and Proteolytic Activity in Irritable Bowel Syndrome.

Enteric Microbiota-Mediated Serotonergic Signaling in Pathogenesis of Irritable Bowel Syndrome